Q-omics provides the consensus-scored MIR649 profile across patient tissues and cancer cell-line models. MIR649 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR649 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR649 RNA expression shows 6,928 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, BRCA, and TGCT as cancer lineages where MIR649 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR649 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR649 survival associations across molecular data types. MIR649 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR649 RNA expression–survival associations across cancer types. High MIR649 expression shows unfavorable associations in BRCA, KIRP, UVM and KICH, but favorable associations in BLCA and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR649 RNA expression.
This table summarizes MIR649 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR649. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR649 shows lower tumor expression in BRCA and PRAD. The BRCA box plot shows higher MIR649 RNA expression in normal versus tumor tissue (log2 FC = −0.095, t-test p = .022).
This table shows molecular features associated with MIR649 in patient tissues and cancer cell lines. In patient samples, MIR649 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
